Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23303792 | 0.83 | KMT2A (0.53) | KDM4EKMT2AHSD17B10LMNAHTT | |
| SCHEMBL23303793 | 0.83 | KMT2A (0.53) | KDM4EKMT2AHSD17B10LMNAHTT | |
| SCHEMBL21399968 | 0.82 | KDM4E (0.47) | KDM4EKMT2AHSD17B10LMNAHTT | |
| Di-Isopropyl Isonicotinamide SCHEMBL4103834 | 0.82 | HPGD (0.50) | KDM4EKMT2AHSD17B10LMNAHTT | |
| SCHEMBL394512 | 0.79 | HSD11B1 (0.53) | KDM4EKMT2ALMNAHDAC4HPGD | |
| SCHEMBL353139 | 0.79 | KDM4E (0.60) | KDM4EKMT2AHSD17B10LMNAHTT | |
| SCHEMBL4000774 | 0.78 | KDM4E (0.47) | KDM4EKMT2AHSD17B10LMNAHTT | |
| SCHEMBL6029641 | 0.78 | HSD17B10 (0.55) | KDM4EHSD17B10HTTGRM1ALDH1A1 | |
| SCHEMBL4503118 | 0.78 | CA1 (0.47) | LMNAHTTHDAC4HPGDALDH1A1 | |
| SCHEMBL12302001 | 0.78 | ALDH1A1 (0.48) | KMT2ALMNAHTTHDAC4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858635-B2 | Spiro compounds as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7671073-B2 | Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080027093-A1 | Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-31 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027093-A1 | Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | KDM4E 389/4885KMT2A 2042/4885HSD17B10 875/4885 |
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | KDM4E 3396/4885KMT2A 2362/4885HSD17B10 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.